BR0113585A - Derivados quinazolina como antagonistas adrenérgicos alfa-1 - Google Patents

Derivados quinazolina como antagonistas adrenérgicos alfa-1

Info

Publication number
BR0113585A
BR0113585A BR0113585-6A BR0113585A BR0113585A BR 0113585 A BR0113585 A BR 0113585A BR 0113585 A BR0113585 A BR 0113585A BR 0113585 A BR0113585 A BR 0113585A
Authority
BR
Brazil
Prior art keywords
alpha
compounds
adrenergic antagonists
quinazoline derivatives
adrenergic
Prior art date
Application number
BR0113585-6A
Other languages
English (en)
Inventor
Cyrus Kephra Becker
Chris Richard Melville
Juerg Roland Pfister
Xiaoming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0113585A publication Critical patent/BR0113585A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS QUINAZOLINA COMO ANTAGONISTAS ADRENéRGICOS ALFA-1". Esta invenção refere-se a compostos que são genericamente antagonistas de receptor de adrenérgico alfa-1B e que são representados pela fórmula genérica (I) onde R^ 1^, R^ 2^, m, n, e A são como definidos no relatório descritivo, ou pró-drogas, isómeros individuais, misturas racêmicas ou não-racêmicas de isómeros, ou seus sais ou solvatos farmaceuticamente aceitáveis. A invenção ainda refere-se a composições farmacêuticas contendo tais compostos, o uso de tais compostos no controle e prevenção de doenças, tais como desordens do trato urinário, disfunção sexual, dor, ou desordens do sistema nervoso central, e processos de sua preparação.
BR0113585-6A 2000-08-31 2001-08-23 Derivados quinazolina como antagonistas adrenérgicos alfa-1 BR0113585A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22950300P 2000-08-31 2000-08-31
PCT/EP2001/009749 WO2002018348A2 (en) 2000-08-31 2001-08-23 Quinazoline derivatives as alpha-1 adrenergic antagonists

Publications (1)

Publication Number Publication Date
BR0113585A true BR0113585A (pt) 2003-07-29

Family

ID=22861517

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113585-6A BR0113585A (pt) 2000-08-31 2001-08-23 Derivados quinazolina como antagonistas adrenérgicos alfa-1

Country Status (19)

Country Link
US (1) US6559153B2 (pt)
EP (1) EP1315714B1 (pt)
JP (1) JP3971299B2 (pt)
KR (1) KR100602929B1 (pt)
CN (1) CN1308324C (pt)
AR (1) AR032475A1 (pt)
AT (1) ATE309240T1 (pt)
AU (2) AU9378801A (pt)
BR (1) BR0113585A (pt)
CA (1) CA2420177C (pt)
DE (1) DE60114852T2 (pt)
ES (1) ES2251512T3 (pt)
GT (1) GT200100181A (pt)
MX (1) MXPA03001777A (pt)
PA (1) PA8527901A1 (pt)
PE (1) PE20020407A1 (pt)
UY (1) UY26919A1 (pt)
WO (1) WO2002018348A2 (pt)
ZA (1) ZA200301082B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1423392B1 (en) 2001-08-10 2006-10-04 Neuro Therapeutics Limited Derivatives of morphine-like opioid compounds
EP1490338B1 (en) * 2002-04-03 2011-08-24 Orion Corporation Use of an alfa2-adrenoreceptor antagonist for cns-related diseases
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
EP1646615B1 (en) * 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
BRPI0412808A (pt) * 2003-07-24 2006-09-26 Euro Celtique Sa compostos de piperidina e composições farmacêuticas contendo os mesmos
WO2006021345A2 (en) * 2004-08-27 2006-03-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with adrenergic alpha-1b receptor (adra1b)
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7413607B2 (en) * 2005-03-31 2008-08-19 3M Innovative Properties Company Templated semiconductor particles and methods of making
US7344583B2 (en) * 2005-03-31 2008-03-18 3M Innovative Properties Company Methods of making metal particles within cored dendrimers
EP1888538B1 (en) * 2005-05-04 2009-11-18 F. Hoffmann-Roche AG (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amines having an activity on the 5-ht receptor
EP3421471B1 (en) 2006-04-25 2021-05-26 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2066584A2 (en) * 2006-09-19 2009-06-10 3M Innovative Properties Company Templated metal oxide particles and methods of making
WO2009047563A1 (en) 2007-10-11 2009-04-16 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
TW200944526A (en) * 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
SI2694056T1 (sl) 2011-04-01 2019-12-31 Astrazeneca Ab Terapevtsko zdravljenje
DK2785349T4 (da) 2011-11-30 2023-01-09 Astrazeneca Ab Kombinationsbehandling af cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
CA3055215A1 (en) 2017-03-12 2018-09-20 Xiaodong Wang Polycyclic amines as opioid receptor modulators
WO2019088095A1 (ja) * 2017-11-02 2019-05-09 国立大学法人九州大学 鎮痛剤及びその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232138A1 (en) 1995-09-29 1997-04-03 William C. Lumma Alpha 1b adrenergic receptor antagonists
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6355641B1 (en) 1999-03-17 2002-03-12 Syntex (U.S.A.) Llc Oxazolone derivatives and uses thereof

Also Published As

Publication number Publication date
JP2004507527A (ja) 2004-03-11
JP3971299B2 (ja) 2007-09-05
DE60114852D1 (de) 2005-12-15
PE20020407A1 (es) 2002-05-21
ZA200301082B (en) 2004-05-07
AU2001293788B2 (en) 2007-10-11
ES2251512T3 (es) 2006-05-01
AU9378801A (en) 2002-03-13
US20020045614A1 (en) 2002-04-18
CA2420177A1 (en) 2002-03-07
CN1308324C (zh) 2007-04-04
KR20030022421A (ko) 2003-03-15
US6559153B2 (en) 2003-05-06
PA8527901A1 (es) 2002-07-30
ATE309240T1 (de) 2005-11-15
UY26919A1 (es) 2002-02-28
EP1315714A2 (en) 2003-06-04
AR032475A1 (es) 2003-11-12
DE60114852T2 (de) 2006-07-27
EP1315714B1 (en) 2005-11-09
GT200100181A (es) 2002-05-23
MXPA03001777A (es) 2003-06-04
CA2420177C (en) 2008-07-08
KR100602929B1 (ko) 2006-07-20
WO2002018348A3 (en) 2002-07-11
CN1545510A (zh) 2004-11-10
WO2002018348A2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
BR0113585A (pt) Derivados quinazolina como antagonistas adrenérgicos alfa-1
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
BR0307406A (pt) Indóis substituìdos como agonistas alfa-1
BRPI0409986A (pt) derivados de pirimidina fundida com atividade de crf
BR9901491A (pt) 7-hetero-biciclo [2.2.1] - heptanos.
BR0315317A (pt) 4-piperazinil benzenossulfonil indóis com afinidade para o receptor de 5-ht6
WO2002024701A3 (en) Substituted azepino[4,5b)indole derivatives
WO2005018557A3 (en) Substituted pyridinones
BR0317600A (pt) ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
PT1259489E (pt) Compostos azapoliciclicos condensados con arilo.
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
RS20050732A (en) Substituted pyrimidinones
BR0116505A (pt) Compostos ou um sal deste farmaceuticamente aceitável, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios onde um antagonista de um receptor de orexina humano é requerido, e, processo para a fabricação de composições farmacêuticas para o tratamento de distúrbios associados com o papel da orexina, especialmente da obesidade e distúrbios do sono
BR0317483A (pt) Derivados de benzodiazepina para o tratamento de desordens neurológicas
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
BR0115291A (pt) Derivados de 2-fenilaminoimidazolina fenil cetona substituìdos como antagonistas de ip
BR0316950A (pt) Derivados de indazol como antagonistas de crf
BR9909253A (pt) Derivados de 2-ariletil-(piperidin-4-ilmetil) amina como antagonistas de receptor muscarìnico
MY140835A (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
BR0207978A (pt) N-but-3enil norbuprenorfina e métodos de uso
BR0111892A (pt) Bis-arilsulfonas
BR0214674A (pt) Derivados 4-piperdinil alquilamina como antagonistas do receptor muscarìnico
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
BR0214649A (pt) Derivados de aminotetralina como antagonistas do receptor muscarìnico
BR0214695A (pt) Derivados de pirazol com anel fundido

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A, 9A E 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.